Avectas is a cell engineering technology business focused on improving the cost, manufacturing and patient outcomes for the next generation of cellular therapies.
Our vision is to position the non-viral Solupore® cell engineering technology to be integrated into manufacturing processes, including complex gene editing, for multiple autologous and allogeneic therapies and commercialized through development and license agreements.
“The key difference between our platform and competing technology is the gentleness. Currently, cells that are being modified are typically from a patient who may be ill and the cells may be fragile.